ananta medicare
ENDLESS CARE ABOUT YOUR HEALTH
#
Great Britain
News
EMA may approve new gene therapy product by Bluebird Bio Company
30.11.2020

European Medicines Agency is considering the application of the American Bluebird Bio for the registration of cerebral adrenoleukodystrophy drug.

To save pharmacists' time a RTEC is being tested in Britain
26.11.2020

Department of the National Health Service of UK in association with the NHS Business Services Authority have developed RTEC based drug dispensing platform.

The effectiveness of an anticoagulant in stroke has been proven
23.11.2020

The FDA has approved the anticoagulant Brilinta for use in patients with cardiovascular disease.

The drug for amyotrophic lateral sclerosis has impressed neurologists
19.11.2020

In a small study, a biotech company has tested its own amyotrophic lateral sclerosis drug.

Osteoporosis - From Idea to Action. Zoleum.
13.11.2020

On 22nd of September 2020 the company "Ananta Medicare" in association with "Clinic of modern rheumatology" held the first webinar on the topic of osteoporosis. The lecture "Osteoporosis - from idea to action" was conducted by prof. Egudina Elizaveta Davydovna.

Swiss company is interested in finding new drug targets
20.10.2020

Scenic Biotech founders and biologists have designed their own functional genomics platform to accurately identify genes that modify a specific disease.

New effective drug for Cushing's syndrome
15.10.2020

The steroidogenesis inhibitor levoketoconazole has improved laboratory parameters in adult patients with endogenous Cushing's disease.

The World Health Organization expects to receive at least 2 billion doses of COVID-19 vaccines next year
08.10.2020

The World Health Organization expects to receive 2 billion doses of COVID-19 vaccines under the COVAX program in 2021.

GALAPAGOS and GILEAD have demonstrated victory over scleroderma
29.09.2020

Experts believe that GALAPAGOS and GILEAD have managed to make a breakthrough on an experimental autotoxin inhibitor in the field of scleroderma therapy.

VIR Biotechnology has demonstrated a new effective drug for hepatitis B prevention
25.09.2020

Clinical studies on VIR-2218 have shown an effective result in the fight against hepatitis B.